1. 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. (5th March 2018) Authors: Harb, W; Abramson, J; Lunning, M; Goy, A; Maddocks, K; Lebedinsky, C; Senderowicz, A; Trojer, P; Bradley, W D; Flinn, I Journal: Annals of oncology Issue: Volume 29(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The Signature Program: Bringing the Protocol to the Patient. Issue 2 (11th May 2015) Authors: Kang, BP; Slosberg, E; Snodgrass, S; Lebedinsky, C; Berry, DA; Corless, CL; Stein, S; Salvado, A Journal: Clinical pharmacology & therapeutics Issue: Volume 98:Issue 2(2015:Aug.) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗